MediciNova says first patient enrolled in EAP trial to evaluate MN-166

MediciNova (MNOV) announced enrollment of the first patient in the NIH-funded Expanded Access Program trial to evaluate MN-166 in patients with Amyotrophic Lateral Sclerosis. This significant milestone marks the beginning of a critical trial aimed at providing access to MN-166 for ALS patients who are not eligible for the ongoing Phase 2/3 COMBAT-ALS trial. The EAP trial, funded by the National Institutes of Health – Neurological Disorders and Stroke, will evaluate the safety and efficacy of MN-166 in approximately 200 ALS patients. Dr. Yuichi Iwaki, President and CEO of MediciNova, commented: “We are honored to support this EAP trial, which will provide MN-166 to more individuals in advanced stages of ALS who are not eligible to our current Phase 2/3 COMBAT-ALS trial. We extend our sincere gratitude to the NIH and NINDS for their support through the Act for ALS. Additionally, we deeply appreciate the participants and their families, as well as the healthcare providers and staff at the sites, whose efforts will make this EAP possible.”